Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2563427 | Pharmacology & Therapeutics | 2011 | 13 Pages |
Abstract
Imbalances in cancer cell redox homeostasis provide a platform for new opportunities in the development of anticancer drugs. The control of severe dose-limiting toxicities associated with redox regulation, including myelosuppression and immunosuppression, remains a challenge. Recent evidence implicates a critical role for redox regulation and thiol balance in pathways that control myeloproliferation, hematopoietic progenitor cell mobilization, and immune response. Hematopoietic stem cell (HSC) self-renewal and differentiation are dependent upon levels of intracellular reactive oxygen species (ROS) and niche microenvironments. Redox status and the equilibrium of free thiol:disulfide couples are important in modulating immune response and lymphocyte activation, proliferation and differentiation. This subject matter is the focus of the present review. The potential of redox modulating chemotherapeutics as myeloproliferative and immunomodulatory agents is also covered.
Keywords
GSTCysRNSGSSGAPCBSOc-Jun NH2-terminal kinaseTrxGPXTh1NACGSHT helper cell type 1Th2T helper cell type 2CySSGRxJnkHSCNF-κBmyeloproliferationHPCsMAPKN-acetyl-cysteineROSionizing radiationthioredoxinThiolSODCancerHematopoietic stem cellDendritic cellantigen presenting cellSuperoxide dismutaseCysteineCystineRedox signalingnuclear factor κBFoxOImmune responsemitogen-activated protein kinasereduced glutathioneglutathione S-transferaseoxidized glutathioneglutathione reductaseglutathione peroxidaseGlutaredoxinreactive nitrogen speciesReactive oxygen species
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Christina L. Grek, Danyelle M. Townsend, Kenneth D. Tew,